Dividends & Buybacks ·
Revelation Biosciences, Inc. stockholders approved a proposal to grant the Board of Directors discretionary authority…
REVBRevelation Biosciences, Inc.
Revelation Biosciences, Inc. stockholders approved a proposal to grant the Board of Directors discretionary authority to effect one or more reverse stock splits between a ratio of 1-for-2 and 1-for-250 within one year of June 24, 2026. The company also amended its bylaws to include universal proxy rules, a formal definition of "Cause" for director and officer removal, and an interim succession framework for the CEO and CFO. Revelation Biosciences, Inc. is a biotechnology company focused on developing immune-based therapies.